{"symbol":"BDX","provider":"yahoo-finance","fetchedAt":"2025-12-26T10:12:40.489Z","asOfDate":"2025-12-26","articles":[{"id":"5e560e71-2557-35bd-b420-aea3aff597ee","title":"Top Stock Reports for AbbVie, Coca-Cola & Chevron","url":"https://finance.yahoo.com/news/top-stock-reports-abbvie-coca-181000803.html","publisher":"Zacks","publishedAt":"2025-12-24T18:10:00.000Z","relatedTickers":["ABBV","AJG","CVX","ICCC","KO","PRPO","RSG"],"mainIdea":"Top Stock Reports for AbbVie, Coca-Cola & Chevron","summary":"Zacks: Top Stock Reports for AbbVie, Coca-Cola & Chevron. ABBV, KO and CVX headline Zacks' top stock reports as analysts flag growth drivers, strategic moves and key headwinds shaping 2025 outlooks. Related tickers mentioned: ABBV, AJG, CVX, ICCC, KO, PRPO, RSG."},{"id":"04db65a9-6dd2-3580-9922-9f0f4efbf72c","title":"Are Options Traders Betting on a Big Move in BD Stock?","url":"https://finance.yahoo.com/news/options-traders-betting-big-move-134600528.html","publisher":"Zacks","publishedAt":"2025-12-24T13:46:00.000Z","relatedTickers":[],"mainIdea":"Are Options Traders Betting on a Big Move in BD Stock?","summary":"Zacks: Are Options Traders Betting on a Big Move in BD Stock?. Investors need to pay close attention to BDX stock based on the movements in the options market lately."},{"id":"b28ef872-a306-3a84-b643-ddaf3af5e392","title":"Becton Dickinson (BDX): Evaluating Valuation After New Immunology Partnership with University of Pennsylvania","url":"https://finance.yahoo.com/news/becton-dickinson-bdx-evaluating-valuation-021624392.html","publisher":"Simply Wall St.","publishedAt":"2025-12-24T02:16:24.000Z","relatedTickers":[],"mainIdea":"Becton Dickinson (BDX): Evaluating Valuation After New Immunology Partnership with University of Pennsylvania","summary":"Simply Wall St.: Becton Dickinson (BDX): Evaluating Valuation After New Immunology Partnership with University of Pennsylvania. Becton Dickinson (BDX) just doubled down on immune system science by teaming up with the University of Pennsylvaniaâ€™s Institute for Immunology and Immune Health to build advanced flow cytometry panels and run a 1,000 patient immune profiling study. See our latest analysis for Becton Dickinson. Those immune profiling and diagnostics wins come as investors are still cautious, with the share price at $195.67 and a year to date share price return of minus 13.61 percent, while the one year total..."}]}
